Volume 14, Issue 3 (volume 14, number 3 2022)                   IJDO 2022, 14(3): 138-144 | Back to browse issues page

XML Print

Assistant Professor of Prevention and Control of Nosocomial Infection, Infectious Diseases Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract:   (206 Views)
Objective: Epidemiological evidence shows that the prevalence of patients with comorbidity of diabetes mellitus (DM), in Coronavirus disease 2019 (COVID-19) is remarkable and they have poor prognosis. We aimed to investigate the comorbidity of diabetes and covid-19 in positive Polymerase Chain Reaction people in Yazd.
Materials and Methods: This retrospective cohort study included data of 570 COVID-19 positive patients, admitted to Shahid Sadoughi Hospital in Yazd, Iran, from February2019 to May 2020, including demographic data and clinical outcome of COVID-19. Study data were analyzed using SPSS software-22 and T-test, Chi-square and a binary logistic regression model were used for modeling.
Results: Prevalence of COVID-19 patients with diabetes was 27% and the percentage of male patients was 62.6%. Additionally, duration of hospitalization significantly higher in diabetic patients (P= 0.004), need to invasive mechanical ventilation in diabetic patients was significantly higher than non-diabetic patients (P˂ 0.001)
Conclusion: DM is one of the most important comorbidity with COVID-19 patients and this comorbidity affects the severity of the disease and the outcome of patients.
Full-Text [PDF 792 kb]   (54 Downloads)    
Type of Study: Research | Subject: Special
Received: 2022/05/5 | Accepted: 2022/08/2 | Published: 2022/09/19

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7]
2. Auwaerter PG. Coronavirus COVID-19 (SARS-2-CoV). Johns Hopkins ABX Guide. 2020. [DOI:10.22627/2072-8107-2020-19-1-5-6]
3. Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. Journal of the Chinese Medical Association. 2021;84(1):3-8. [DOI:10.1097/JCMA.0000000000000463]
4. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021;397(10285):1646-57. [DOI:10.1016/S0140-6736(21)00677-2]
5. Richardson S, Gitlin J, Kozel Z, Levy S, Rahman H, Hirsch JS, et al. In-Hospital 30-Day Survival Among Young Adults with COVID-19: A Cohort Study. InOpen Forum Infectious Diseases 2021. [DOI:10.1093/ofid/ofab233]
6. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. New England Journal of Medicine. 2013;368(24):2277-85. [DOI:10.1056/NEJMoa1305584]
7. Placzek HE, Madoff LC. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. American journal of public health. 2014;104(11):e118-25. [DOI:10.2105/AJPH.2014.302197]
8. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Jama The Journal of the American Medical Association (JAMA). 2003;289(21):2801-9. [DOI:10.1001/jama.289.21.JOC30885]
9. Alqahtani FY, Aleanizy FS, Mohamed RA, Alanazi MS, Mohamed N, Alrasheed MM, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiology & Infection. 2019;147. [DOI:10.1017/S0950268818002923]
10. Ayenigbara IO, Adeleke OR, Ayenigbara GO, Adegboro JS, Olofintuyi OO. COVID-19 (SARS-CoV-2) pandemic: fears, facts and preventive measures. Germs. 2020 ;10(3):218. [DOI:10.18683/germs.2020.1208]
11. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes care. 2018;41(10):2127-35. [DOI:10.2337/dc18-0287]
12. Mirzaei M, Rahmaninan M, Mirzaei M, Nadjarzadeh A. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC public health. 2020;20(1):1-9. [DOI:10.1186/s12889-020-8267-y]
13. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific reports. 2017;7(1):1-0. [DOI:10.1038/s41598-017-13379-z]
14. Sheikhpour R, Jalali-KhanAbadi BA, Yaghmaei P, Salmani M, Afkhami Ardakani M. The effect of zinc supplemention on glycosylated hemoglobin in type II diabetic patients. Journal of Shahrekord Uuniversity of Medical Sciences. 2011;12 (4):58-63.(in Persian)
15. Lotfi MH, Saadati H, Afzali M. Prevalence of diabetes in people aged≥ 30 years: the results of screen-ing program of Yazd Province, Iran, in 2012. Journal of research in health sciences. 2013;14(1):88-92.
16. Katibeh M, Hosseini S, Soleimanizad R, Manaviat MR, Kheiri B, Khabazkhoob M,et al. Prevalence and risk factors of diabetes mellitus in a central district in Islamic Republic of Iran: a population-based study on adults aged 40-80 years. EMHJ-Eastern Mediterranean Health Journal. 2015;21(6):412-9. https://doi.org/10.26719/2015.21.6.412 [DOI:10.26719/2015.21.412]
17. Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID‐19 and diabetes mellitus. Journal of diabetes investigation. 2020;11(5):1104-14. [DOI:10.1111/jdi.13326]
18. Fadini GP, Morieri ML, Longato E, Avogaro DA. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of endocrinological investigation. 2020;43(6):867-9. [DOI:10.1007/s40618-020-01236-2]
19. Wang PH, Cheng Y. Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. BioRxiv. 2020. [DOI:10.1101/2020.02.24.963348]
20. Edagawa S, Kobayashi F, Kodama F, Takada M, Itagaki Y, Kodate A, et al. Epidemiological features after emergency declaration in Hokkaido and report of 15 cases of COVID-19 including 3 cases requiring mechanical ventilation. Global Health & Medicine. 2020. [DOI:10.35772/ghm.2020.01024]
21. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes/metabolism research and reviews. 2020;36(7):e3319. [DOI:10.1002/dmrr.3319]
22. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 ;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3]
23. Mirjalili H, Dastgheib SA, Shaker SH, Bahrami R, Mazaheri M, Sadr-Bafghi SM, et al. Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis. Journal of Diabetes & Metabolic Disorders. 2021 ;20(1):905-17. [DOI:10.1007/s40200-021-00768-5]
24. Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Archives for Chest Disease. 2020;90(2). [DOI:10.4081/monaldi.2020.1389]
25. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes. Journal of medical virology. 2021;93(3):1449-58. [DOI:10.1002/jmv.26424]
26. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585]
27. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology. 2020 ;5(7):802-10. [DOI:10.1001/jamacardio.2020.0950]
28. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020 ;75(7):1730-41. [DOI:10.1111/all.14238]
29. Liang Y, Wang ML, Chien CS, Yarmishyn AA, Yang YP, Lai WY, et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Frontiers in immunology. 2020 ;11:1022. [DOI:10.3389/fimmu.2020.01022]
30. Elemam NM, Hannawi H, Al Salmi I, Naeem KB, Alokaily F, Hannawi S. Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates. Saudi Medical Journal. 2021;42(2):170. [DOI:10.15537/smj.2021.2.25700]
31. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Critical care medicine. 2020 ;48(8):e657. [DOI:10.1097/CCM.0000000000004411]
32. Moftakhar L, Moftakhar P, Piraee E, Ghaem H, Valipour A, Azarbakhsh H. Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients. International journal of diabetes in developing countries. 2021;41(3):383-8. [DOI:10.1007/s13410-021-00930-y]
33. Soliman A, Nair AP, Al Masalamani MS, De Sanctis V, Khattab MA, Alsaud AE, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Bio Medica: Atenei Parmensis. 2020;91(3):e2020010.
34. Akbariqomi M, Hosseini MS, Rashidiani J, Sedighian H, Biganeh H, Heidari R, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: A single-center, retrospective study in Iran. Diabetes research and clinical practice. 2020 ;169:108467. [DOI:10.1016/j.diabres.2020.108467]
35. Chen Y, Chen J, Gong X, Rong X, Ye D, Jin Y, et al. Clinical characteristics and outcomes of type 2 diabetes patients infected with COVID-19: a retrospective study. Engineering. 2020 ;6(10):1170-7. [DOI:10.1016/j.eng.2020.05.017]
36. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020 ;14(4):535-45. [DOI:10.1016/j.dsx.2020.04.044]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.